Epidemiological and clinical aspects of cardiovascular diseases in new coronavirus infection
https://doi.org/10.25789/YMJ.2021.73.18
Abstract
A review of the literature data on the epidemiological and clinical aspects of cardiovascular diseases in the new coronavirus infection is presented. Summarizing the results of studies by many authors, we state that the tropism of the new coronavirus infection to the cardiovascular system is manifested through ACE2 receptors, immune, cytokine inflammation, increased coagulation activity. These pathophysiological characteristics are especially manifested in concomitant cardiovascular pathology, leading to decompensation of the existing pathology and often death. Thus, cardiovascular disease is a dangerous risk factor for the development of fatal consequences in the current pandemic situation.
About the Authors
S. I. Sofronova
Yakut science centre of complex medical problems
Russian Federation
Russian Federation
Sofronova Sargylana Ivanovna, PhD, Chief Researcher
The Republic of Sakha (Yakutia), Yakutsk, Yaroslavskogo, 6/3
M. P. Kirillina
Yakut science centre of complex medical problems
Russian Federation
Russian Federation
Kirillina Maria Petrovna, PhD, Leading Researcher
The Republic of Sakha (Yakutia), Yakutsk, Yaroslavskogo, 6/3
V. M. Nikolaev
Yakut science centre of complex medical problems
Russian Federation
Russian Federation
Nikolaev Vyacheslav Mikhailovich, PhD, Chief Researcher
The Republic of Sakha (Yakutia), Yakutsk, Yaroslavskogo, 6/3
A. N. Romanova
Yakut science centre of complex medical problems
Russian Federation
Russian Federation
Romanova Anna Nikolaevna, MD, director
The Republic of Sakha (Yakutia), Yakutsk, Yaroslavskogo, 6/3
I. V. Kononova
Yakut science centre of complex medical problems
Russian Federation
Russian Federation
Kononova Irina Vasilievna, Researcher
The Republic of Sakha (Yakutia), Yakutsk, Yaroslavskogo, 6/3
References
1. https://стопкоронавирус.рф
2. Annakan V Navaratnam. Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data/ Annakan V Navaratnam, William K Gray, Jamie Day [et al.] // The Lancet Respiratory Medicine, Published: February 15, 2021. https://doi.org/10.1016/S2213-2600(20)30579-8
3. Arentz M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State / M, Arentz, E. Yim, L. Klaff // JAMA. 2020;323:1612–1614.
4. Argulian E. Right ventricular dilation in hospitalized patients with COVID-19 infection / E. Argulian, K. Sud, B. Vogel [et al.] // JACC Cardiovasc Imaging. Published online. - May 15, 2020. doi:10.1016/j.jcmg.2020.05.010
5. Bourgonje A.R. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) / A.R.Bourgonje, A.E.Abdulle, W. Timens [et al.] // J Pathol.- 2020 Jul; No 251(3). – P.228-248. doi: 10.1002/path.5471
6. Caforio A.L.Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases / A.L. Caforio, S. Pankuweit, E. Arbustini // Eur Heart J. 2013;34:2636–2648.
7. Center for Disease Control and Prevention. Hypertension statistics and maps. https://www.cdc.gov/bloodpressure/statistics_maps.htm
8. Center for Disease Control and Prevention. Diabetes data and statistics. https://www.cdc.gov/diabetes/data/index.html
9. Center for Disease Control and Prevention. Overweight & obesity - data & statistics. https://www.cdc.gov/obesity/data/index.html
10. Chen L. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARSCoV-2 / L. Chen, X. Li, M. Chen, Y. Feng, C. Xiong // Cardiovasc Res. 2020;116(6):1097-1100. doi:10.1093/cvr/cvaa078
11. Clerkin K.J. COVID-19 and cardiovascular disease / K.J. Clerkin, J.A. Fried, J. Raikhelkar // Circulation. 2020;141:1648–1655.
12. Coomes E.A. Interleukin-6 in COVID-19: A systemic review and meta-analysis / E.A. Coomes, H. Haghbayan // Rev. Med. Virol. 2020; e2141. DOI: 10.1002/rmv.2141.
13. Cunningham J.W. Clinical Outcomes in Young US Adults Hospitalized With COVID-19 / J.W. Cunningham, M. Vaduganathan, B.L. Claggett [et al.] // JAMA Intern Med. 2020. Sep 9. doi: 10.1001/jamainternmed.2020.5313
14. Driggin E, Madhavan MV, Bikdeli B [et al.] Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic / Driggin E, Madhavan MV, Bikdeli B [et al.] // J Am Coll Cardiol 2020;75(18):2352-2371. https://doi.org/10.1016/j.jacc.2020.03.031
15. Epidemiology Working Group for Ncip Epidemic Response CCfDC, Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151. https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003
16. Felix Kwenandar. Coronavirus disease 2019 and cardiovascular system: A narrative review / Felix Kwenandar, Karunia Valeriani Japar, Vika Damay [et al.] // Int J Cardiol Heart Vasc. 2020 Jun 3;29:100557. doi: 10.1016/j.ijcha.2020.100557
17. Gro S. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications / S. Gro, C. Jahn, S. Cushman [et al.] // J Mol Cell Cardiol. 2020 Jul;144:47-53. doi:10.1016/j.yjmcc.2020.04.031
18. Henry B.M. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis / B.M. Henry, M.H.C. de Oliveira, S. Benoit [et al.] // Clin. Chem. Lab. Med. 2020; 58 (7): 1021–1028. DOI: 10.1515/ cclm-2020-0369.
19. Huang C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China / C. Huang, Y. Wang, X. Li [et al.] // Lancet 2020; 395: 497–506
20. Inciardi R.M. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) / R.M. Inciardi, L. Lupi, G. Zaccone // JAMA Cardiol. 2020;5:819–824.
21. Imam Z. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States / Z. Imam, F. Odish, I. Gill [et al.] // J Intern Med. 2020;288(4):469–76. https://doi.org/10.1111/joim.13119.
22. Januzzi J.L. Troponin and BNP use in COVID-19 / J.L. Januzzi // Cardiology Magazine. March. 2020;18 https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-andbnp-use-in-covid19
23. Kang S.J. Age-related morbidity and mortality among patients with COVID-19 / S.L. Kang, S.I. Jung // Infect Chemother. 2020;52(2):154–64.
24. Kevin J Clerkin. COVID-19 and Cardiovascular Disease / Kevin J Clerkin, Justin A Fried, Jayant Raikhelkar [et al.] // Circulation. 2020 May 19;141(20):1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941.
25. Kim I.C. COVID-19-related myocarditis in a 21-year-old female patient / I.C. Kim, J.Y. Kim, H.A. Kim, S. Han // Eur Heart J. 2020;41:1859.
26. Kociol R.D. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association / R.D. Kociol, L.T. Cooper, J.C. Fang // Circulation. 2020; 141:e69–e92.
27. Komarowska I. Hepatocyte growth factor receptor c-Met instructs T cell cardiotropism and promotes t cell migration to the heart via autocrine chemokine release / I. Komarowska, D. Coe, G. Wang // Immunity. 2015;42:1087–1099.
28. Lee D.W. Current concepts in the diagnosis and management of cytokine release syndromeBl / D.W. Lee, R. Gardner, D.L. Porter. Blood. 2014;124:188–195.
29. Li S. Clinical and pathological investigation of patients with severe COVID-19 / S. Li, L. Jiang, X. Li [et al.] // JCI Insight. 2020;5(12):138070. Published 2020 Jun 18. doi: 10.1172/jci.insight.138070
30. Liu K. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province / K. Liu, Y.Y. Fang, Y. Deng // Chin Med J. 2020;133:1025–1031.
31. Lu R. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding / R. Lu, X. Zhao, J. Li [et al.] // Lancet. 2020; 395: 565–574.
32. Novel Coronavirus (2019-nCoV) global situation reports; World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
33. Peretto G. Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation / G. Peretto, S. Sala, S. Rizzo // J Am Coll Cardiol. 2020;75:1046–1057.
34. Peretto G. Arrhythmias in myocarditis: state of the art / G. Peretto, S. Sala, S. Rizzo // Heart Rhythm. 2019;16:793–801.
35. Richardson S. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area / S. Richardson, J.S. Hirsch, M. Narasimhan [et al.] // JAMA 2020. https://doi.org/10.1001/jama.2020.6775
36. Rokni M. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS / M. Rokni, V. Ghasemi, Z. Tavakoli // Rev Med Virol. 2020;30(3): e2107. doi:10.1002/rmv.2107
37. Sala S. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection / S. Sala, G. Peretto, M. Gramegna // Eur Heart J. 2020;41:1861–1862.
38. Sato R. A review of sepsis-induced cardiomyopathy / R. Sato, M. Nasu // J Intensive Care. 2015;3:48.
39. Shi S. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China / M. Qin, B. Shen [et al.] // JAMA Cardiol.2020. https://doi.org/10.1001/jamacardio.2020.0950
40. Siddhartha Dan, Mohit Pant, Sushil Kumar Upadhyay. The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic / Siddhartha Dan, Mohit Pant, Sushil Kumar Upadhyay // Curr Pharmacol Rep. 2020 Sep 15;1-10. doi: 10.1007/s40495-020-00239-0
41. Sukrit Narula. Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis / Sukrit Narula, Salim Yusuf, Michael Chong [et al.] // The Lancet. 2020; Vol. 396, No. 10256: 968–976. DOI: 10.1016/S0140-6736(20)31964-4
42. Szekely Y. The spectrum of cardiac manifestations in coronavirus disease 2019 (COVID19)—a systematic echocardiographic study / Y. Szekely, Y. Lichter, P. Taieb [et al.] // Circulation. 2020;142(4):342-353. doi:10.1161/CIRCULATIONAHA.120.047971
43. Tegally H. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa / H. Tegally, E. Wilkinson, M. Giovanetti [et al.] // MedRxiv. 2020; (published online Dec 22.) (preprint). https://doi.org/10.1101/2020.12.21.20248640
44. Tian W. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis / W. Tian, W. Jiang, J. Yao [et al.] // J. Med. Virol. 2020; 92 (10):1875–1883. DOI: 10.1002/jmv.26050.
45. Udomsinprasert W. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis / W. Udomsinprasert, J. Jittikoon, S. Sangroongruangsri, U. Chaikledkaew // J Clin Immunol. 2021 Jan;41(1):11-22. doi: 10.1007/s10875-020-00899-z.
46. Volz E. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. medRxiv. 2021; (published online Jan 4.) / E. Volz, S. Mishra, M. Chand [et al.] (preprint). https://doi.org/10.1101/2020.12.30.20249034
47. Wan S. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) / S. Wan, Q. Yi, S. Fan [et al.] // MedRxiv. 2020. doi:10.1101/2020.02.10.20021832
48. Wang D. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China / D. Wang, B. Hu, C. Hu [et al.] // JAMA. 2020;323:1061–1069. https://doi.org/10.1001/jama.2020.1585
49. Xiong T.Y. Coronaviruses and the cardiovascular system: acute and long-term implications / T.Y. Xiong, S. Redwood, B. Prendergast, M. Chen // Eur Heart J 2020;41(19):1798-1800. https://doi.org/10.1093/eurheartj/ehaa231
50. Yanez N.D. COVID-19 mortality risk for older men and women / N.D. Yanez, N.S. Weiss, J.A. Romand [et al.] // BMC Public Health 20, 1742 (2020). https://doi.org/10.1186/s12889-020-09826-8
51. Ying-Ying Zheng. COVID-19 and the cardiovascular system / Ying-Ying Zheng, Yi-Tong Ma, Jin-Ying Zhang, Xiang Xie // Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
52. Yu C.M. Cardiovascular complications of severe acute respiratory syndrome /C.M. Yu, R.S. Wong, E.B. Wu [et al.] // Postgrad Med J 2006;82(964):140-4. https://doi.org/10.1136/pgmj.2005.037515
53. Zeng J-H. First case of COVID-19 infection with fulminant myocarditis complication: case report and insights / J-H. Zeng, Y-X. Liu, J. Yuan // Published online April 10. Infection. 2020 doi: 10.1007/s15010-020-01424-5.
54. Zhang J.J. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China / J.J. Zhang, X. Dong, Y.Y. Cao [et al.] // Allergy. - 2020; 75(7):1730-1741. doi:10.1111/all.14238
55. Zhang Q. Clinical trial analysis of 2019-nCoV therapy registered in China J Med Virol / Q. Zhang, Y. Wang, C. Qi [et al.]. – No 92 (2020), P. 540-545
56. Zhao D. Epidemiology of cardiovascular disease in China: current features and implications / D. Zhao, J. Liu, M. Wang [et al.] // Nat Rev Cardiol 2019;16(4):203-212. https://doi.org/10.1038/s41569-018-0119-4
57. Zheng Y.Y. COVID-19 and the cardiovascular system / Y.Y. Zheng, Y.T. Ma, J.Y. Zhang, X. Xie // Nat Rev Cardiol 2020;17(5):259-260. https://doi.org/10.1038/s41569-020-0360-5
Review
For citations:
Sofronova S.I., Kirillina M.P., Nikolaev V.M., Romanova A.N., Kononova I.V. Epidemiological and clinical aspects of cardiovascular diseases in new coronavirus infection. Yakut Medical Journal. 2021;(1):64-69. https://doi.org/10.25789/YMJ.2021.73.18
Views:
16
Email this article 